Nxera Pharma Secures $1.8M Milestone from Centessa for Orexin Receptor Drug
Event summary
- Nxera Pharma to receive $1.8M milestone payment from Centessa Pharmaceuticals for ORX489 development.
- Payment triggered by early development milestone for neuropsychiatric disorder treatment.
- Revenue recognized in Q1 2026.
- ORX489 is an orally administered orexin receptor 2 (OX2R) agonist.
The big picture
This payment underscores the strategic value of Nxera's NxWave™ GPCR platform in attracting partnerships for neuropsychiatric drug development. The deal reflects growing industry interest in orexin receptor targets for central nervous system disorders. Nxera's ability to monetize its platform through milestone payments could enhance its financial stability and support further pipeline expansion.
What we're watching
- Pipeline Progress
- Whether Centessa can advance ORX489 through clinical development and trigger additional milestones.
- Revenue Impact
- How this payment contributes to Nxera's financial performance in 2026.
- Partnership Dynamics
- The pace at which Nxera can secure similar milestone payments from other collaborations.